PR, Media News, Client Updates & Observations from Absolutely PR in Denver


Follow on Twitter (since June 2008):
Read Client Pitches & Placements (since July 2005):
Checkout Denver PR Newsroom (since March 2002):

HOMECONTACTLeadershipBrand ExperienceNewsSocial/Digital MediaE-PortfolioResultsOnline ExposureWhy PR?How PR?News HooksBlog - UpdatesIRPR.US

Wednesday, September 17, 2014

Three Colorado Bioscience Companies Present at the Inaugural White Hat Life Science Investor Conference in Phoenix
Colorado BioScience Association (CBSA) congratulates the three Colorado headquartered companies selected to present at the inaugural White Hat Life Science Investor Conferencebeing held September 17 and 18 at the Grand Hyatt in Phoenix, AZ. The announcement is made by April Giles, CBSA President and CEO, who says, “We’re excited to be a partner in the 2014 White Hat Life Science Investor Conference and to help showcase three of Colorado’s promising bioscience companies during the event.” The participating Colorado companies include EndoShape, Fluonic and ViroCyt.

The conference, spearheaded by the Arizona BioIndustry Association (AZBio), is presented by the National Venture Capital Association and leading life science associations of the Rocky Mountain Southwest Region, including the CBSA. This conference is showcasing 34 of the region’s top life science companies to interested investors including business development professionals from large pharmaceutical, biotechnology, medical device and diagnostic companies.

“The Rocky Mountain and Southwest Regions have become increasingly recognized for their growth in the bioscience and heath care innovations. The White Hat Life Science Investor Conference will act as another opportunity to highlight the work being done in Colorado and the surrounding region while at the same time bringing new potential partners and investors into our community,” Giles said. 

Colorado bioscience companies selected to present in the 2014 White Hat Investor Conference:

EndoShape, Inc., Boulder – EndoShape’s mission is to commercialize novel medical devices based on its proprietary polymer technology. EndoShape is focused on the coil embolization and occlusion market. EndoShape is currently commercializing the Medusa™ Vascular Plug which is FDA 510(k) cleared for sale in the United States. Visit,

Fluonic, Inc., Boulder - Fluonic is a privately held medical device company dedicated to making infusion drug delivery safer for patients through the development of a new generation of infusion devices and information systems, driven by a breakthrough MEMS flow sensor technology. Fluonic infusion products improve patients’ safety and compliance while improving medical staff productivity and reducing costs, which will set a new standard of care for the industry. Visit,

ViroCyt, LLC, Boulder - ViroCyt, LLC was created in late 2012 to focus on the commercialization of novel technologies that enable rapid quantification of viruses, such as the Virus Counter® 3100. The Company’s mission is to provide the tools that deliver meaningful improvements to critical biotechnology processes such as vaccine manufacturing, protein expression, antiviral development and other settings where viruses play a significant role. Visit,

For more information and a complete listing of presenting companies, visit the conference website at

3:25 pm edt          Comments

Tuesday, September 16, 2014

Video Highlights: BioWest 2014, Marriott City Center, Denver
BioWest 2014 Video Highlights

Founders Breakfast Health and Wellness Panel: Introductions BySteve VanNurden -

Health/Wellness Panel: Jandel Allen-Davis on the Kaiser Model - 

Health/Wellness Panel: James Hill on Extreme Weight Loss TV -

Health/Wellness Panel: Len Tacconi on What Works - 

C-Level Unplugged: Larry Gold, Chairman of the Board, SomaLogic - 
C-Level Unplugged: Shar Matin, COO, Spectranetics - 
CEO Panel: Bill Aldrich, CEO, EndoShape -

CEO Panel: David Brunel, CEO, Biodesix -

CEO Panel: Byron Hewett, CEO, SomaLogic - 

BioTalks Excerpt:Jonathan Norris – Investments, Exits -

BioTalks Excerpt: David Gary, Clinical Trials Ethics -

BioTalks Excerpt: Iya Khalil on Big Data Healthcare -

BioTalks Excerpt: Robert Atkinson, How Colorado Ranks -

BioTalks Excerpt: Rhea May, Superbugs -

BioTalks Excerpt: Larry Blankenship, Valley of Death -

BioTalks Excerpt: Mark Sirangelo, Innovation in Colorado -

BioTalks Excerpt: Lindsay Guerdrum, Beer Bioscience - 

Russell Slifer – About the USPTO -

Russell Slifer – USPTO Rocky Mtn Regional Office - 
Venture Showcase Sponsors and Judges

dBMEDx Winning Venture Showcase Presentation -

KromaTiD Venture Showcase Presentation -

Mighty Oak Medical Venture Showcase Presentation - 

FDA Commissioner Hamburg Opening Remarks to Closing Keynote -

Link to the related InnovatioNews article

Link to the related Denver Post article

Link to the related Denver Business Journal article
4:20 pm edt          Comments

Colorado Med Device Company dBMEDx Wins the Venture Showcase Competition at BioWest 2014
dBMEDx (Littleton)won the 2014 Venture Showcase competition at the BioWest Conference and Expo yesterday at the Marriott City Center Denver, receiving the $7,500 cash prize. The announcement is made by April Giles, Colorado BioScience Association (CBSA) President and CEO who says, “We are very proud to announce dBMEDx as the winner of the Venture Showcase. The check presentation was an exciting end to the BioWest Conference. The award not only includes the cash prize of $7,500 but also includes recognition and exposure for the company. ” This award is sponsored by Dorsey and Whitney LLP and The Metro Denver Economic Development Corporation. BioWest, the Rocky Mountain Region's premier medical device and biotechnology conference, is organized by the CBSA and held every other year. 

dBMEDx is a Colorado-based medical device development company that is creating clinical decision and patient monitoring devices using its patented, non-invasive scanning technology. These devices combine the power and safety of ultrasound with sophisticated image processing electronics and software to provide simple, fully automated and completely noninvasive diagnostic measurements.  Fully automated means that very little training is required and the user does not need any experience with ultrasound to use our devices. To enable this level of automation, dBMEDx has successfully created and patented an extremely compact, wireless, 3D scan engine.

The scan engine, which can be held in the palm of the hand, includes a complete 3D ultrasound imaging machine and automated image processor within a small, sealed tube.  The system also includes an integrated Bluetooth radio and rechargeable battery, which is inductively charged. The company is in the process of commercializing the first application for this technology, the BBS Revolution™ device for automated bladder volume measurement, and has a range of pipeline of products for other clinical applications as well. Visit:

Video of winning Venture Showcase pitch by dBMEDx CEO David Shine: 

The Venture Showcase format allowed each company’s lead executive to make a 15-minute presentation with an accompanying slide deck explaining their technology and business plan to a panel of judges in front of a live audience. This year's judging panel included the following:

• Michael Weiner, Partner, Dorsey
• Ned Scheetz, Managing Director, Aphelion Capital
• Steve VanNurden, President and CEO, Fitzsimons Redevelopment Authority

The three 2014 Venture Showcase finalists included:

dBMEDx – Littleton
KromaTiD, Inc. - Fort Collins
Mighty Oak Medical – Englewood

The BioWest Conference was attended by more than 300 industry leaders, government representatives, executives, researchers, investors and entrepreneurs. “We look forward to the continued growth of the bioscience industry and presenting the conference in again 2016,” Giles concludes.

Link to the related Business Wire

Link to the PitchEngine Social Media Release 
2:04 pm edt          Comments

Monday, July 7, 2014

New Issue: Bioscience Colorado Magazine 2014-15 Article Overview



Make sure to check out these "great reads" -- and save the new directory for future use.

The complete flip book of the issue can be found online at:

Articles - Direct Links:

Mobile Health in Colorado: Where “Big Data” Sparks Big Ideas 
Biodesix Harnesses Machine Learning and Analytics to Tackle Multivariate Diagnostics 
Bioscience in Colorado Continues to Shine with U.S. Senator Michael Bennet 
Colorado Life Science Assets: A Sophisticated Repertoire of Clinical-Stage Therapeutic, Device and Diagnostic Products 
U.S. Hub: Colorado Is Where Drug, Device and Therapy Intersect 
Boettcher Investigators: Webb-Waring Biomedical Research Program 
Found in Translation: Rocky Mountain Lions Eye Institute Translational Research Programs Focus on Innovative Treatment of Eye Diseases 
Tech Transfer Offices Connect the Dots between Research and the Marketplace, Stimulate State’s Economy 
Colorado Bioscience Industry by the Numbers: Financing and Acquisitions 
Colorado Bioscience Grant Programs: Innovation Engines 
Colorado Bioscience Industry Directory – updated company information – great to keep on file 

Bioscience Colorado magazine is an integral part of the Association’s mission to support the Colorado bioscience community through advocacy, resources and advancement of opportunities for collaboration. It reaches thousands of bioscience, economic development, legislative, university and industry leaders. Colorado’s bioscience assets are also valuable. Device, diagnostic and therapeutic products created here have a significant economic impact—27,000 in total workforce— translating to over $10 billion in the State’s economy each year. In addition, over 60 acquisitions, financings and grants, totaling over $4 billion, were reported within the 2013 calendar year, further developing the industry’s ecosystem. 

Download the new magazine pdf at:

2:56 pm edt          Comments

Tuesday, June 3, 2014

Colorado BioScience Association Praises Boettcher Foundation As It Embarks on the Fifth Year of Its Webb-Waring Biomedical Research Program



Seven early-career scientists are joining the ranks ofBoettcher Investigators in the Webb-Waring Biomedical Research Program, with today’s announcement from Theodore F. Schlegel, M.D., Chairman of the Boettcher Foundation Board of Trustees.

“The Boettcher Foundation Board is pleased to celebrate our fifth class in this very specialized and important niche of biomedical research,” Schlegel said. “Our investigators now number 29, and several of our early Investigators are already achieving significant advancements in their areas of research.”

The 2014 Class of Boettcher Investigators in the Webb-Waring Biomedical Research Program includes:

* Kunhua Song, PhD, University of Colorado Anschutz Medical Campus, Assistant Professor of Medicine - Regenerative medicine and heart development/disease

* Roger A. Bannister, PhD, University of Colorado Anschutz Medical Campus, Assistant Professor of Medicine, Cardiology Division - Skeletal and cardiac muscle physiology

* Subhajyoti De, PhD, University of Colorado Anschutz Medical Campus, Assistant Professor of Biomedical Informatics and Personalized Medicine - Cancer genomics; lung cancer; somatic mutations; DNA damage and repair; algorithm development; optimization

* Loren Hough, PhD, University of Colorado Boulder, Assistant Professor of Physics - Structural biology of order and disordered proteins

* Christopher L. Gentile, PhD, Colorado State University, Assistant Professor of Food Science and Human Nutrition - Molecular causes of vascular dysfunction

* Amy B. Dounay, PhD, Colorado College, Assistant Professor of Chemistry and Biochemistry - Medicinal chemistry for African Sleeping Sickness

* Rachel L. Zemans, MD, National Jewish Hospital, Assistant Professor of Medicine - Resolution of Alveolar Epithelial Permeability after Lung Injury

“The new class of Boettcher Investigators represents some of the finest scientific minds in the state, and we are honored to have the opportunity to support their research, which has the potential to have significant impacts on human health,” said Tim Schultz, President and Executive Director of the Boettcher Foundation.  

Boettcher Investigators are awarded grants of $225,000, covering up to three years of research with a goal for these early-career scientists to establish themselves and become competitive for major awards from federal agencies and private foundations. With the addition of the 2014 Class, there are now 29 Boettcher Investigators conducting research in the following Colorado institutions: University of Colorado Anschutz Medical Campus, University of Colorado Boulder, Colorado State University, National Jewish Health, Colorado School of Mines and Colorado College.

The Webb-Waring Biomedical Research Program was created in 2008, as the result of an innovative agreement among the Boettcher Foundation, the Webb-Waring Foundation for Biomedical Research and the University of Colorado. Through the program, the Boettcher Foundation now invests more than $1.5 million each year into efforts to increase Colorado's competitiveness in biomedical science.

Link to the full release

Link to the related Business Wire release

6:02 pm edt          Comments

2014.09.01 | 2014.07.01 | 2014.06.01 | 2014.05.01 | 2014.04.01 | 2014.03.01 | 2013.09.01 | 2013.08.01 | 2012.12.01 | 2012.09.01 | 2012.07.01 | 2012.06.01 | 2012.03.01 | 2012.02.01 | 2011.12.01 | 2011.11.01 | 2011.10.01 | 2011.09.01 | 2011.06.01 | 2011.05.01 | 2010.12.01 | 2010.09.01 | 2010.08.01 | 2010.07.01 | 2010.05.01 | 2010.04.01 | 2010.03.01 | 2010.02.01 | 2010.01.01

Link to web log's RSS file

The Absolutely PR Blog is listed on Blog Catalog: